Studies On The Synthesis Ofβ-Cyclodextrin-Epirubicin Inclusion Complexe And Its Interaction With The Cancer Cell

In recent years, Malignant tumors become one of the most serious diseases, ranking in the first cause of death. In cancer therapy, chemotherapy is usually used method in the clinical treatment of cancer, but most chemotherapy drugs lack of targeting so that the body’s normal cells are damaged. This has led to serious side effects and the low rate of response to chemotherapy. Thus to look for promising drug targeting is one of the effective means to improve the effect of chemotherapy and reduce drug toxicity. In this paper, the supermolecular inclusion of epirubicin (EPI) with β-cyclodextrin (β-CD) is firstly studied in aqueous solution and the mechanism of action of the EPI and the breast cancer oncogene DNA is explored by fluorescence spectroscopy. The release rate of EPI from the cavity of β-CD was investigated in vitro to adjust the pH value; and the cell morphology and cell toxicity test further confirm the inclusion in the intracellular release. The main contents are as follows:1. The supermolecular inclusion of epirubicin (EPI) with β-cyclodextrin (β-CD) was firstly studied in aqueous solution by fluorescence spectroscopy. The effects of reaction temperature, reaction time and concentration of β-CD on the inclusion efficiency of EPI were investigated. The results show that fluorescence intensity of EPI was enhanced about two times after formation of1:2inclusion complexe with β-CD. At36℃, pH7.4, the inclusion constant was8.14×103(L/mol)2.2. Using the above inclusion compound, the mechanisms of interaction of the anticancer drug EPI and breast cancer oncogene DNA, interaction of ssDNA and dsDNA with the EPI and inclusion complexe were investigated, respectively. Interaction of dsDNA containing different amount of G, C base pairs with the EPI and inclusion complexe was investigated, respectively. Fluorescence quenching of the DNA on the EPI increases with the amount of GC base. This shows that the mode of action of the EPI and the DNA is embedded between GC base pair. The drug molecules into the cavity of β-CD has been hampered by the drug molecules with DNA in the aqueous environment of pH7.4. This offers the possibility for sustained release of drugs.3. On this basis, we further investigate the controlled release of the inclusion complexe, The effect of pH was investigated first by the in vitro release rate of EPI from the β-CD cavity, EPI cumulative release rate of EPI was achieved36.1%and26.1%when the pH was5and7.4, respectively. Feasibility based on the inclusion compound into breast cancer cells was used to examine the interaction of the inclusion compound with breast cancer, cell morphology and cell toxicity test. The result provides a good reference for EPI release clinical application.